Hepatic triglyceride synthesis pathway — Drug Target

All drugs that target Hepatic triglyceride synthesis pathway — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Omega-3 fatty acid

Marketed (1)

• Omacor® · Hospital Universitari Vall d'Hebron Research Institute · Omega-3 fatty acid · Cardiovascular
  Omacor is a prescription omega-3 fatty acid formulation that reduces triglyceride levels by decreasing hepatic triglyceride synthesis and increasing fatty acid oxidation.

Phase 3 pipeline (1)

• AMR101 · Massachusetts General Hospital · Omega-3 fatty acid · Cardiovascular
  AMR101 is a high-purity eicosapentaenoic acid (EPA) that reduces triglycerides by inhibiting hepatic triglyceride synthesis and enhancing fatty acid oxidation.